SPECIMAN RESOURCE CORE

标本资源核心将使用现有的基础设施来满足翻译的广泛需求 目前标本采集、诊断和分配不能满足的两种皮肤癌研究 共享设施。该核心将从事收集、储存和分发广泛的标本和 试剂、标本分析和试剂验证。此外，它还将开发新的方法来 多重样本分析、DNA和RNA提取和扩增、综合数据库系统、 和计算分析。更具体地说，核心将：a)在现有汇辑的基础上发展和扩展 皮肤癌的翻译研究样本，包括正常皮肤，黑素细胞病变，黑色素瘤， BCC、血清和循环淋巴细胞，确保其正确存储、注释并及时分发到 孢子调查员；b)协调构建痣/黑色素瘤组织微阵列和测试/细胞 C)验证抗体和TMA结果；d)建立和维护一个中央数据库程序 基本的病理、临床、流行病学、随访信息和基础研究数据 与生物信息学/统计核心相结合；e)提供特殊服务，如分析 用于临床试验、突变、染色质修饰和对新药反应的样本；f)维护 并分发所需的经过验证的试剂(抗体、寡核苷酸、DNA、RNA、质粒、蛋白质) 肿瘤和细胞分析；g)带头开发新的标本诊断方法，例如 稀缺植物标记的多重分析及mRNA和DNA的分离和扩增程序 标本；以及h)与耶鲁大学的共享设施和其他机构的类似资源建立联系， 包括其他孢子。该核心将与生物信息学、临床试验办公室、 耶鲁综合癌症的免疫学、关键技术和遗传学共享设施 中心。标本资源核心的服务将提高翻译工作的效率 以具有成本效益的方式对孢子进行研究，并加快将发现应用于 临床实践，并将临床成果转化为基础研究。

The Specimen Resource Core will use existing infrastructure to address the broad needs of translational studies in two skin cancers that are not met by current specimen acquisition, diagnosis and distribution shared facilities. The core will engage in collecting, storing and distribution of a wide range of specimens and reagents, specimen analysis and reagent verification. In addition, it will develop new approaches for multiplex specimen analysis, DNA and RNA extraction and amplification, comprehensive database systems, and computational analysis. More specifically, the core will: a) build on and extend the current repertoire of specimens for translational studies in skin cancers, including normal skin, melanocytic lesions, melanoma, BCC, serum and circulating lymphocytes, ensuring their proper storage, annotation, and timely distribution to SPORE investigators; b) coordinate the construction of nevi/melanoma tissue microarrays and test/cell arrays; c) validate antibodies and TMA results; d) establish and maintain a central database program of essential pathological, clinical, epidemiological, follow-up information and basic research data that will be integrated with the bioinformatics/statistics core; e) provide special services such as the analysis of specimens for clinical trials, mutations, chromatin modification, and responses to novel drugs; f) maintain and distribute verified reagents (antibodies, oligonucleotides, DNA, RNA, plasmids, proteins) needed for tumor and cell analyses; g) spearhead the development of new approaches for specimen diagnosis, such as multiplex analysis of markers, isolation and amplification procedures for mRNA and DNA from scarce specimens; and h) establish links with shared facilities at Yale and similar resources in other institutions, including other SPOREs. This core will interact extensively with the Bioinformatics, Clinical Trial Office, Immunology, Critical Technologies, and Genetics shared facilities of the Yale Comprehensive Cancer Center. The services of the Specimen Resource Core will enhance the efficient operation of the translational studies in the SPORE in a cost-effective manner, and expedite the application of discoveries at the bench to clinical practice, and clinical results to basic research.